/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Irvine, California-based Edwards Lifesciences Corporation (EW) provides products and technologies to treat advanced cardiovascular diseases in the United States and internationally. With a market cap of $45.3 billion, the company is set to unveil its second-quarter results on Thursday, July 24, after the market closes.
Ahead of the event, analysts expect EW to report non-GAAP earnings of $0.62 per share, down 11.4% from the profit of $0.70 per share reported in the year-ago quarter. Additionally, the company has surpassed or matched the Street’s bottom-line projections in each of the past four quarters, which is impressive.